Symbols / VTGN Stock $0.66 -1.12% Vistagen Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
VTGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Shawn K. Singh J.D.
Exch · Country NCM · United States
Market Cap 27.19M
Enterprise Value -16.86M
Income -69.69M
Sales 1.27M
FCF (ttm) -40.50M
Book/sh 0.90
Cash/sh 1.11
Employees 41
Insider 10d —
IPO Jun 21, 2011
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.60
PEG —
P/S 21.43
P/B 0.74
P/C —
EV/EBITDA 0.23
EV/Sales -13.29
Quick Ratio 3.55
Current Ratio 3.67
Debt/Eq 2.94
LT Debt/Eq —
EPS (ttm) -1.81
EPS next Y -1.11
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-06-15
ROA -67.84%
ROE -131.59%
ROIC —
Gross Margin 100.00%
Oper. Margin -35.95%
Profit Margin 0.00%
Shs Outstand 41.03M
Shs Float 35.80M
Insider Own 0.19%
Instit Own 40.79%
Short Float 7.27%
Short Ratio 2.47
Short Interest 2.02M
52W High 5.14
vs 52W High -87.11%
52W Low 0.43
vs 52W Low 54.12%
Beta 0.29
Impl. Vol. 3.88%
Rel Volume 0.71
Avg Volume 878.89K
Volume 623.67K
Target (mean) $0.97
Tgt Median $1.00
Tgt Low $0.90
Tgt High $1.00
# Analysts 3
Recom Hold
Prev Close $0.67
Price $0.66
Change -1.12%
About

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$0.97
Mean price target
2. Current target
$0.66
Latest analyst target
3. DCF / Fair value
$-17.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.66
Low
$0.90
High
$1.00
Mean
$0.97

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-17 down William Blair Outperform → Market Perform —
2025-12-17 down Maxim Group Buy → Hold —
2025-12-17 down Jefferies Buy → Hold $1
2023-12-07 up Jefferies Hold → Buy $15
2023-11-14 init Stifel — → Buy $12
2023-09-05 main Maxim Group Buy → Buy $30
2023-08-07 up Maxim Group Hold → Buy $30
News
RSS: Latest VTGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-31 PRINCE JOSHUA S Chief Operating Officer — 4,386 $0.56 $2,468
2025-06-30 SINGH SHAWN K Chief Executive Officer — 7,541 $1.70 $12,820
2025-06-30 ADLER REID G. Officer — 7,541 $1.70 $12,820
2025-06-30 ANDERSON CYNTHIA LYNN Chief Financial Officer — 6,617 $1.70 $11,249
2025-06-30 PRINCE JOSHUA S Chief Operating Officer — 4,882 $1.70 $8,299
2024-12-31 ANDERSON CYNTHIA LYNN Chief Financial Officer — 2,592 $2.51 $6,499
2024-12-31 PRINCE JOSHUA S Chief Operating Officer — 3,310 $2.51 $8,300
2024-06-28 SINGH SHAWN K Chief Executive Officer — 4,854 $2.96 $14,358
2024-06-28 ADLER REID G. General Counsel — 4,854 $2.96 $14,358
2024-06-28 ANDERSON CYNTHIA LYNN Chief Financial Officer — 3,592 $2.96 $10,625
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Total Revenue
1.27
+161.11%
0.49
-54.32%
1.06
+568.72%
-0.23
Operating Revenue
1.27
+161.11%
0.49
-54.32%
1.06
+568.72%
-0.23
Operating Expense
73.39
+30.00%
56.46
+65.64%
34.09
-42.27%
59.04
Research And Development
54.97
+39.62%
39.38
+96.66%
20.02
-54.88%
44.38
Selling General And Administration
18.42
+7.83%
17.08
+21.48%
14.06
-4.10%
14.66
Selling And Marketing Expense
—
—
—
1.90
General And Administrative Expense
18.42
+7.83%
17.08
+21.48%
14.06
-4.10%
14.66
Salaries And Wages
—
—
—
6.29
Other Gand A
18.42
+7.83%
17.08
+21.48%
14.06
-4.10%
14.66
Total Expenses
73.39
+30.00%
56.46
+65.64%
34.09
-42.27%
59.04
Operating Income
-72.13
-28.86%
-55.97
-69.51%
-33.02
+44.29%
-59.27
Total Operating Income As Reported
-72.13
-28.86%
-55.97
-69.51%
-33.02
+44.29%
-59.27
EBITDA
-71.39
-29.01%
-55.34
-70.52%
-32.45
+44.75%
-58.74
Normalized EBITDA
-71.39
-29.01%
-55.34
-70.52%
-32.45
+44.75%
-58.74
Reconciled Depreciation
0.73
+15.43%
0.64
+11.80%
0.57
+6.77%
0.53
EBIT
-72.13
-28.86%
-55.97
-69.51%
-33.02
+44.29%
-59.27
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Write Off
—
—
—
0.00
Net Income
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Pretax Income
-69.68
-35.53%
-51.41
-75.12%
-29.36
+50.44%
-59.24
Net Non Operating Interest Income Expense
2.44
-46.43%
4.56
+35.99%
3.35
+12788.46%
0.03
Interest Expense Non Operating
—
—
—
0.02
Net Interest Income
2.44
-46.43%
4.56
+35.99%
3.35
+12788.46%
0.03
Interest Expense
—
—
—
0.02
Interest Income Non Operating
2.44
-46.43%
4.56
+35.99%
3.35
+6738.78%
0.05
Interest Income
2.44
-46.43%
4.56
+35.99%
3.35
+6738.78%
0.05
Other Income Expense
0.01
+40.00%
0.01
-98.40%
0.31
—
Other Non Operating Income Expenses
0.01
+40.00%
0.01
-98.40%
0.31
—
Tax Provision
0.01
+0.00%
0.01
+75.00%
0.00
-33.33%
0.01
Tax Rate For Calcs
0.00
+90.48%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Net Income From Continuing Operation Net Minority Interest
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Net Income From Continuing And Discontinued Operation
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Net Income Continuous Operations
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Normalized Income
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Net Income Common Stockholders
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Diluted EPS
-1.83
-9.58%
-1.67
-9.87%
-1.52
+82.14%
-8.51
Basic EPS
-1.83
-9.58%
-1.67
-9.87%
-1.52
+82.14%
-8.51
Basic Average Shares
38.07
+23.31%
30.88
+59.53%
19.35
+178.10%
6.96
Diluted Average Shares
38.07
+23.31%
30.88
+59.53%
19.35
+178.10%
6.96
Diluted NI Availto Com Stockholders
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Insurance And Claims
—
—
—
1.38
Preferred Stock Dividends
—
—
—
—
Rent And Landing Fees
—
—
—
0.42
Rent Expense Supplemental
—
—
—
0.42
Total Other Finance Cost
—
—
-3.35
-12788.46%
-0.03
Line Item Trend 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Total Assets
48.56
-42.42%
84.34
-31.79%
123.65
+486.34%
21.09
Current Assets
46.94
-42.81%
82.08
-31.98%
120.67
+589.28%
17.51
Cash Cash Equivalents And Short Term Investments
45.40
-43.59%
80.48
-32.46%
119.17
+616.23%
16.64
Cash And Cash Equivalents
30.79
-54.14%
67.13
-43.67%
119.17
+616.23%
16.64
Other Short Term Investments
14.61
+9.46%
13.35
0.00
—
Receivables
—
—
—
0.80
Other Receivables
—
—
—
0.80
Prepaid Assets
—
—
—
—
Current Deferred Assets
—
—
0.07
+10.45%
0.07
Other Current Assets
1.54
-3.39%
1.59
+5.84%
1.51
+87.78%
0.80
Total Non Current Assets
1.62
-28.43%
2.27
-24.02%
2.98
-16.78%
3.58
Net PPE
1.23
-32.19%
1.81
-19.69%
2.25
-18.50%
2.77
Gross PPE
2.30
-28.43%
3.21
-8.38%
3.51
-11.39%
3.96
Accumulated Depreciation
-1.07
+23.58%
-1.40
-11.96%
-1.25
-5.11%
-1.19
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.24
+113.27%
0.11
+413.64%
0.02
-45.00%
0.04
Other Properties
1.87
-35.23%
2.88
-11.98%
3.27
-11.68%
3.71
Leases
0.19
-12.22%
0.22
+3.27%
0.21
+0.00%
0.21
Non Current Deferred Assets
—
—
0.62
-12.46%
0.71
Non Current Prepaid Assets
—
—
0.10
+0.00%
0.10
Other Non Current Assets
0.39
-13.44%
0.45
-37.47%
0.73
—
Total Liabilities Net Minority Interest
13.04
-6.50%
13.95
+48.94%
9.37
+3.97%
9.01
Current Liabilities
12.79
+1.45%
12.61
+146.18%
5.12
+12.00%
4.57
Payables And Accrued Expenses
9.97
+63.31%
6.10
+182.15%
2.16
-26.23%
2.93
Payables
1.53
+135.07%
0.65
-57.79%
1.55
-37.44%
2.47
Accounts Payable
1.53
+135.07%
0.65
-57.79%
1.55
-37.44%
2.47
Current Accrued Expenses
8.43
+54.72%
5.45
+784.74%
0.62
+34.20%
0.46
Pensionand Other Post Retirement Benefit Plans Current
0.32
-90.39%
3.36
+107.54%
1.62
+380.42%
0.34
Current Debt And Capital Lease Obligation
0.80
+41.71%
0.56
+2.00%
0.55
-6.94%
0.59
Current Debt
0.10
—
—
0.10
Current Capital Lease Obligation
0.70
+24.60%
0.56
+2.00%
0.55
+13.17%
0.49
Current Deferred Liabilities
1.71
-33.93%
2.59
+227.18%
0.79
+10.78%
0.71
Current Deferred Revenue
1.71
-33.93%
2.59
+227.18%
0.79
+10.78%
0.71
Total Non Current Liabilities Net Minority Interest
0.25
-81.40%
1.34
-68.45%
4.24
-4.31%
4.43
Long Term Debt And Capital Lease Obligation
0.25
-73.73%
0.95
-39.62%
1.57
-25.94%
2.12
Long Term Capital Lease Obligation
0.25
-73.73%
0.95
-39.62%
1.57
-25.94%
2.12
Tradeand Other Payables Non Current
—
—
—
—
Non Current Deferred Liabilities
0.00
-100.00%
0.39
-85.38%
2.67
+15.51%
2.31
Non Current Deferred Revenue
0.00
-100.00%
0.39
-85.38%
2.67
+15.51%
2.31
Stockholders Equity
35.52
-49.54%
70.39
-38.41%
114.29
+846.08%
12.08
Common Stock Equity
35.52
-49.54%
70.39
-38.41%
114.29
+846.08%
12.08
Capital Stock
0.04
+37.93%
0.03
+7.41%
0.03
+285.71%
0.01
Common Stock
0.04
+37.93%
0.03
+7.41%
0.03
+285.71%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
39.62
+36.63%
29.00
+7.29%
27.03
+269.49%
7.32
Ordinary Shares Number
39.62
+36.64%
29.00
+7.30%
27.03
+269.66%
7.31
Treasury Shares Number
0.00
+0.00%
0.00
+0.00%
0.00
+0.02%
0.00
Additional Paid In Capital
516.77
+7.22%
481.96
+1.58%
474.44
+38.36%
342.89
Retained Earnings
-477.32
-17.10%
-407.63
-14.43%
-356.21
-8.98%
-326.85
Gains Losses Not Affecting Retained Earnings
-0.00
-140.00%
0.01
0.00
—
Treasury Stock
3.97
+0.00%
3.97
+0.00%
3.97
+0.00%
3.97
Other Equity Adjustments
-0.00
-140.00%
0.01
—
—
Total Equity Gross Minority Interest
35.52
-49.54%
70.39
-38.41%
114.29
+846.08%
12.08
Total Capitalization
35.52
-49.54%
70.39
-38.41%
114.29
+846.08%
12.08
Working Capital
34.15
-50.84%
69.46
-39.88%
115.55
+793.44%
12.93
Invested Capital
35.62
-49.40%
70.39
-38.41%
114.29
+837.92%
12.19
Total Debt
1.04
-30.82%
1.51
-28.82%
2.12
-21.80%
2.71
Capital Lease Obligations
0.95
-37.18%
1.51
-28.82%
2.12
-18.65%
2.61
Net Tangible Assets
35.52
-49.54%
70.39
-38.41%
114.29
+846.08%
12.08
Tangible Book Value
35.52
-49.54%
70.39
-38.41%
114.29
+846.08%
12.08
Current Notes Payable
0.10
0.00
0.00
-100.00%
0.10
Line Item Trend 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Operating Cash Flow
-66.44
-57.82%
-42.10
-63.08%
-25.81
+48.08%
-49.72
Cash Flow From Continuing Operating Activities
-66.44
-57.82%
-42.10
-63.08%
-25.81
+48.08%
-49.72
Net Income From Continuing Operations
-69.69
-35.53%
-51.42
-75.12%
-29.36
+50.44%
-59.25
Depreciation Amortization Depletion
0.73
+15.43%
0.64
+11.80%
0.57
+6.77%
0.53
Depreciation
0.73
+15.43%
0.64
+11.80%
0.57
+6.77%
0.53
Depreciation And Amortization
0.73
+15.43%
0.64
+11.80%
0.57
+6.77%
0.53
Other Non Cash Items
—
—
—
3.56
Stock Based Compensation
4.00
-7.37%
4.32
+97.75%
2.18
-34.59%
3.34
Asset Impairment Charge
—
—
—
0.00
Operating Gains Losses
—
—
0.01
-92.31%
0.08
Gain Loss On Investment Securities
—
—
—
0.08
Gain Loss On Sale Of PPE
0.00
0.00
-100.00%
0.01
0.00
Change In Working Capital
-0.94
-119.71%
4.76
+500.25%
0.79
-60.88%
2.03
Change In Prepaid Assets
0.04
+140.91%
-0.09
-135.20%
0.25
-92.16%
3.19
Change In Payables And Accrued Expense
0.83
-85.43%
5.68
+988.31%
0.52
+155.89%
-0.93
Change In Other Working Capital
-1.24
-459.01%
-0.22
-143.02%
0.52
+150.49%
0.21
Change In Other Current Liabilities
-0.56
+8.18%
-0.61
-23.43%
-0.49
-14.32%
-0.43
Investing Cash Flow
-0.88
+93.33%
-13.15
-21454.10%
-0.06
+91.76%
-0.74
Cash Flow From Continuing Investing Activities
-0.88
+93.33%
-13.15
-21454.10%
-0.06
+91.76%
-0.74
Net PPE Purchase And Sale
-0.15
+20.94%
-0.19
-213.11%
-0.06
+71.23%
-0.21
Purchase Of PPE
-0.15
+20.94%
-0.19
-213.11%
-0.06
+71.23%
-0.21
Capital Expenditure
-0.15
+20.94%
-0.19
-213.11%
-0.06
+71.23%
-0.21
Net Investment Purchase And Sale
-0.73
+94.40%
-12.96
0.00
—
Purchase Of Investment
-22.30
+10.74%
-24.98
0.00
—
Sale Of Investment
21.57
+79.39%
12.03
0.00
—
Net Business Purchase And Sale
—
—
0.00
+100.00%
-0.53
Purchase Of Business
—
—
0.00
+100.00%
-0.53
Financing Cash Flow
30.97
+864.83%
3.21
-97.50%
128.40
+12434.49%
-1.04
Cash Flow From Continuing Financing Activities
30.97
+864.83%
3.21
-97.50%
128.40
+12434.49%
-1.04
Net Issuance Payments Of Debt
0.10
0.00
+100.00%
-0.98
+4.74%
-1.03
Issuance Of Debt
1.02
0.00
—
—
Repayment Of Debt
-0.93
0.00
+100.00%
-0.98
+4.74%
-1.03
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
-0.00
Net Long Term Debt Issuance
—
—
—
-0.00
Short Term Debt Issuance
1.02
0.00
—
—
Short Term Debt Payments
-0.93
0.00
+100.00%
-0.98
+4.74%
-1.03
Net Short Term Debt Issuance
0.10
0.00
+100.00%
-0.98
+4.74%
-1.03
Net Common Stock Issuance
30.64
+918.44%
3.01
-97.67%
129.38
+184927.14%
-0.07
Common Stock Payments
—
—
—
-0.17
Repurchase Of Capital Stock
—
—
—
-0.17
Proceeds From Stock Option Exercised
0.23
+14.93%
0.20
+2412.50%
0.01
-87.30%
0.06
Changes In Cash
-36.34
+30.16%
-52.03
-150.75%
102.53
+299.10%
-51.50
Beginning Cash Position
67.13
-43.67%
119.17
+616.23%
16.64
-75.58%
68.14
End Cash Position
30.79
-54.14%
67.13
-43.67%
119.17
+616.23%
16.64
Free Cash Flow
-66.59
-57.46%
-42.29
-63.44%
-25.87
+48.18%
-49.93
Interest Paid Supplemental Data
0.03
0.00
—
—
Income Tax Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-0.54
-39.59%
-0.39
0.00
—
Common Stock Issuance
30.64
+918.44%
3.01
-97.67%
129.38
+124302.88%
0.10
Issuance Of Capital Stock
30.64
+918.44%
3.01
-97.67%
129.38
+124302.88%
0.10
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category